Revolution Medicines, Inc.RVMD
NasdaqGS•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $0, declining NaN% year-over-year. TTM net income stood at $-1.37B (96.7% contraction). Quarterly EBITDA was $-442.88M and operating income was $-445.22M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze RVMD growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters